CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine

被引：112

作者：

Eliasson, Dubravka Grdic ^{[1
]}

El Bakkouri, Karim ^{[2
]}

Schoen, Karin ^{[1
]}

Ramne, Anna ^{[3
]}

Festjens, Els ^{[2
]}

Lowenadler, Bjorn ^{[4
]}

Fiers, Walter ^{[2
]}

Saelens, Xavier ^{[2
]}

Lycke, Nits ^{[1
]}

机构：

[1] Univ Gothenburg, Inst Biomed, Mucosal Immunol & Vaccine Res Ctr, Dept Microbiol & Immunol, S-40530 Gothenburg, Sweden

[2] Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium

[3] Biovitrum AB, Gothenburg, Sweden

[4] AstraZeneca, Gothenburg, Sweden

来源：

VACCINE | 2008年 / 26卷 / 09期

关键词：

mucosal vaccination; IgA immunity; influenza A virus; immunomodulation; mucosa; spleen and lymph nodes; rodent; antigens/peptides/epitopes; targeted adjuvants;

D O I：

10.1016/j.vaccine.2007.12.027

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

At present few vaccine candidates exists against potentially pandemic influenza virus infections. We provide compelling evidence that a targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope, CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high We-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-We CD4 T cell immunity. This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1243 / 1252

页数：10

共 67 条

[1]

ABRAMOWICZ M, 2003, MED LETT DRUGS THER, V45, P65

[2]

Agren LC, 1997, J IMMUNOL, V158, P3936

[3] The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization [J].